Inhibition of lung tumourigenesis by sulindac: Comparison of two experimental protocols

Carcinogenesis

Volumn 18, Issue 3, 1997, Pages 491-496

  Castonguay, Andre ^a   Rioux, Nathalie ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; SULINDAC; TOBACCO SMOKE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNOMODULATION; LUNG CARCINOGENESIS; METHODOLOGY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SHEEP ERYTHROCYTE; SMOKING;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; CARCINOGENS; CYCLOOXYGENASE INHIBITORS; DIET; DINOPROSTONE; DISEASE SUSCEPTIBILITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOLYTIC PLAQUE TECHNIQUE; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MICE; MICE, INBRED A; NITROSAMINES; PLANTS, TOXIC; SMOKE; STOMACH NEOPLASMS; SULINDAC; TOBACCO;

EID: 0031408201     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/18.3.491     Document Type: Article

References (54)

1. Castonguay, A. (1992) Methods and strategies in lung cancer control. Cancer Res., 52, 2641s-2651s.
2. Hammond, W.G. and Benfield, J.R. (1993) Hamster bronchial carcinogenesis induced by carcinogen-containing sustained release implants placed endobronchially: a clinically relevant model. J. Cell. Biochem., Suppl. 17F, 104-107.
3. Hecht, S.S., Isaacs, S. and Trushin, N. (1994) Lung tumour induction in A/J mice by the tobacco smoke carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene: a potentially useful model for evaluation of chemopreventive agents. Carcinogenesis, 15, 2721-2725.
4. Fisher, S., Castonguay, A., Kaiserman, K., Spiegelhalder, B. and Preussmann, R. (1990) Tobacco-specific nitrosamines in Canadian cigarettes. J. Cancer Res. Clin. Oncol., 116, 563-568.
5. Hecht, S.S. (1994) Metabolic activation and detoxification of tobacco-specific nitrosamines - A model for cancer prevention strategies. Drug Metab. Rev., 26, 373-390.
6. Wynder, E.L. and Hoffmann, D. (1994) Smoking and lung cancer: Scientific challenges and opportunities. Cancer Res., 54, 5284-5295.
7. Hoffmann, D., Rivenson, A., Murphy, S.E., Chung, F.-L., Amin, S. and Hecht, S.S. (1993) Cigarette smoking and adenocarcinoma of the lung: The relevance of nicotine-derived N-nitrosamines. J. Smoking-Related. Dis., 4, 165-189.
8. 6-Methylguanine is a critical determinant of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone tumorigenesis in A/J mouse lung. Cancer Res., 51, 5557-5564.
9. Hecht, S.S., Morse, M.A., Amin, S., Stoner, G.D., Jordan, K.G., Choi, C.-I. and Chung, F.-L. (1989) Rapid single-dose model for lung tumour induction in A/J mice by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and the effect of diet. Carcinogenesis, 10, 1901-1904.
10. Belinsky, S.A., Devereux, T.R., Foley, J.F., Maronpot, R.R. and Anderson, M.W. (1992) Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res., 52, 3164-3173.
11. Lin, J.M., Desai, D.H., Morse, M.A., Amin, S. and Hecht, S.S. (1992) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone pulmonary metabolism and tumorigenicity in mice by analogues of the investigational chemotherapeutic drug 4-ipomeanol. Chem. Res. Toxicol., 5, 674-679.
12. Hong, J.Y., Wang, Z.Y., Smith, T.J., Zhou, S., Shi, S., Pan, J. and Yang, C.S. (1992) Inhibitory effects of diallyl sulfide on the metabolism and tumorigenicity of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mouse lung. Carcinogenesis, 13, 901-904.
13. Morse, M.A., LaGreca, S.D., Amin, S.G. and Chung, F-L. (1990) Effects of indole-3-carbinol on lung tumorigenesis and DNA methylation induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on the metabolism and disposition of NNK in A/J mice. Cancer Res., 50, 2613-2617.
14. Wattenberg, L.W. and Coccia, J.B. (1991) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone carcinogenesis in mice by D-limonene and citrus fruit oils. Carcinogenesis, 12, 115-117.
15. Hecht, S.S., Morse, M.A., Eklind, K.I. and Chung, F-L. (1991) A/J mouse lung tumorigenesis by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by arylalkyl isothiocyanates. Exp. Lung. Res., 17, 501-511.
16. Wang, Z.Y., Hong, J.Y., Huang, M.T., Reuhl, K.R., Conney, A.H. and Yang, C.S. (1992) Inhibition of N-nitrosodiethylamine-and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced tumorigenesis in A/J mice by green tea and black tea. Cancer Res., 52, 1943-1947.
17. Castonguay, A., Pepin, P. and Stoner, G.D. (1991) Lung tumorigenicity of NNK given orally to A/J mice: its application of chemopreventive efficacy studies. Exp. Lung Res., 17, 485-499.
18. Jalbert, G. and Castonguay, A. (1992) Effects of NSAIDs on NNK-induced pulmonary and gastric tumorigenesis in A/J mice. Cancer Lett., 66, 21-28.
19. Pepin, P., Rossignol, G. and Castonguay, A. (1990) Inhibition of NNK-induced lung tumorigenesis in A/J mice by ellagic acid and butylated hydroxyanisole. Cancer J., 3, 266-273.
20. Boukharta, M., Jalbert, G. and Castonguay, A. (1992) Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice. Nutr. Cancer, 18, 181-189.
21. Shimkin, M.B. and Stoner, G.D. (1975) Lung tumors in mice: application to carcinogenesis bioassay. Adv. Cancer Res., 21, 1-58.
22. Hudson, L. and Hay, F. C. (1989) Practical Immunology 3rd Edition, Oxford: Blackwell Scientific, pp. 140-141.
23. Stoner, G.D. (1991) Lung tumors in strain A mice as a bioassay for carcinogenicity of environmental chemicals. Exp. Lung Res., 17, 405-423.
24. Foley, J.F., Anderson, M.W., Stoner, G.D., Gaul, B.W., Hardisty, J.F. and Maronport, R.R. (1991) Proliferative lesions in the mouse lung: Progression studies in strain A mice. Exp. Lung Res., 17, 157-168.
25. Devesa, S.S., Shaw, G.L. and Blot, W.J. (1991) Changing patterns of lung cancer incidence by histological type. Cancer Epidemiol. Biomarkers Prev., 1, 29-34.
26. Belinsky, S.A., Stefanski, S.A. and Anderson, M.W. (1993) The A/J mouse lung as a model for developing new chemointervention strategies. Cancer Res., 53, 410-416.
27. Stoner, G.D., Greisiger, E.A., Schut, H.A.J., Pereira, M.A., Loeb, T.R., Klaunig, J.E. and Branstetter, D.G. (1984) A comparison of the lung adenoma response in strain A/J mice after intraperitoneal and oral administration of carcinogens. Toxicol. Appl. Pharmacol., 72, 313-323.
28. 6-methylguanine formation and metabolism of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Cancer Res., 49, 2894-2897.
29. Stoner, G.D., Adam-Rodwell, G. and Morse, M.A. (1993) Lung tumors in strain A mice: application for studies in cancer chemoprevention. J. Cellular Biochem., Suppl. 17F, 95-103.
30. Bouchard, L. and Castonguay, A. (1993) Inhibitory effects of nonsteroidal anti-inflammatory drugs (NSAIDs) on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in mouse lung explants. Drug Metab. Disp., 21, 293-298.
31. Fischer, S., Spiegelhalder, B. and Preussmann, R. (1990) Tobacco-specific nitrosamines in European and USA cigarettes. Arch. Geschwulstforsch, 60, 169-177.
32. Pepin, P. Bouchard, L., Nicole, P. and Castonguay, A. (1992) Effects of sulindac and oltipraz on the tumorigenicity of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in A/J mouse lung. Carcinogenesis, 13, 341-348.
33. Duperron, C. and Castonguay, A. Chemoprevention efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis (in press).
34. Schreinemachers, D.M. and Everson, R.B. (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology., 5, 138-146.
35. Moorghen, M., Ince, P., Finney, K.J., Sunter, J.P., Appleton, D.R. and Watson, A.J. (1988) A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol., 156, 341-347.
36. Giardiello, F.M., Hamilton, S.R., Krush, A.J., Piantadosi, S., Hylind, L.M., Celano, P., Booker, S.V., Robinson, C.R., and Offerhaus, J.A. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328, 1313-1316.
37. Holt, P.G. (1987) Immune and inflammatory function in cigarette smokers. Thorax, 42, 241-249.
38. Gerrard, J.W., Heiner, D.C., Ko, C.G., Mink, J., Meyers, A. and Dosman, J.A. (1980) Immunoglobulin levels in smokers and non-smokers. Annl. Allergy, 44, 261-262.
39. Wayneforth, H.B. and Magee, P.N. (1974) The effects of N-nitroso-N-methylurea and N-dimethylnitrosamine on cell-mediated and humoral immune responses in rats and mice. Br. J. Cancer, 30, 512-523.
40. Hard, G.C., (1981) Effect of a single carcinogenic dose of dimethylnitrosamine on antibody responses in the rat. Oncology, 38, 47-52.
41. Desjardins, R., Fournier, M., Denizeau, F. and Krzystyniak, K. (1992) Immunosupression by chronic exposure to N-nitrosodimethylamine (NDMA) in mice. J. Toxicol. Environ. Health, 37, 351-361.
42. Kaminski, N.E., Jordan, S.D., Page, D., Kim, B.S. and Holsapple, M.P. (1989) Suppression of humoral responses by dialkylnitrosamines: Structure-activity relationships. Fundam. Appl. Toxicol., 12, 321-332.
43. Rivenson, A., Hoffmann, D., Prokopczyk, B., Amin, S. and Hecht, S.S. (1988) Induction of lung and exocrine pancreas tumours in F344 rats by tobacco-specific and Areca-derived N-nitrosamines. Cancer Res., 48, 6912-6917.
44. Oreffo, V.I.C., Lin, H-W., Padmanabhan, R. and Witschi, H. (1993) K-ras and p53 point mutations in 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced hamster lung tumours Carcinogenesis, 14, 451-455.
45. Hecht, S.S., Rivenson, A., Braley, J., DiBello, J., Adams, J.D. and Hoffmann, D. (1986) Induction of oral cavity tumours in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res., 46, 4162-4166.
46. 6-methylguanine formation in Clara cells and induction of pulmonary neoplasia in the rat by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res., 50, 3772-3780.
47. Rioux, N. and Castonguay, A. NSAIDs mediated recovery of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced immunosuppression in A/J mice. J. Natl Cancer Inst. (submitted).
48. Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol., 231, 232-235.
49. Flowers, R.J. (1974) Drugs which inhibit prostaglandin biosynthesis. Pharmacol. Rev., 26, 33-67.
50. Lala, P.K. and Searloos, M.N. (1994) Prostaglandins and the host immune system: application of prostaglandin inhibitors for cancer immunotherapy. In: Prostaglandin inhibitors in tumor immunology and immunotherapy. CRC Press, Boca Raton, Chapter 7.
51. Reddy, B. S., Rao, C. V., Rivenson, A. and Kelloff, G. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14, 1493-1497.
52. Boolbol, S.K., Dannenberg, A.J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J.T., Abreu-Goris, M., Newmark, H.L., Lipkin, M.L., DeCosse, J.J. and Bertagnolli, M.M. (1996) Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56, 2556-2560.
53. Alberts, D.S., Hixson, L., Ahnen, D., Bogert, C., Einspahr, J., Paranka, N., Brendel, K., Gross, P.H., Pamucku, R. and Burt, R.W. (1995) Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase. J. Cell. Biochem., Suppl. 22, 18-23.
54. Piazza, G.A., Rahm, A.L.K., Krutzsch, M., et al. (1995) Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55, 3110-3116.